Abstract:The development of therapeutic interventions for diseases necessitates a crucial step known as drug screening, wherein potential substances with medicinal properties are rigorously evaluated. This process has undergone a transformative evolution, driven by the imperative need for more efficient, rapid, and high-throughput screening platforms. Among these, microfluidic systems have emerged as the epitome of efficiency, enabling the screening of drug candidates with unprecedented speed and minimal sample consumption. This review paper explores the cutting-edge landscape of microfluidic-based drug screening platforms, with a specific emphasis on two pioneering approaches: organ-on-a-chip and C. elegans-based chips. Organ-on-a-chip technology harnesses human-derived cells to recreate the physiological functions of human organs, offering an invaluable tool for assessing drug efficacy and toxicity. In parallel, C. elegans-based chips, boasting up to 60% genetic homology with humans and a remarkable affinity for microfluidic systems, have proven to be robust models for drug screening. Our comprehensive review endeavors to provide readers with a profound understanding of the fundamental principles, advantages, and challenges associated with these innovative drug screening platforms. We delve into the latest breakthroughs and practical applications in this burgeoning field, illuminating the pivotal role these platforms play in expediting drug discovery and development. Furthermore, we engage in a forward-looking discussion to delineate the future directions and untapped potential inherent in these transformative technologies. Through this review, we aim to contribute to the collective knowledge base in the realm of drug screening, providing valuable insights to researchers, clinicians, and stakeholders alike. We invite readers to embark on a journey into the realm of microfluidic-based drug screening platforms, fostering a deeper appreciation for their significance and promising avenues yet to be explored.

In vivo quantitative high-throughput screening for drug discovery and comparative toxicology

Identification of Small-Molecule Ion Channel Modulators in C. Elegans Channelopathy Models.

A High-throughput Assay for the Prediction of Chemical Toxicity by Automated Phenotypic Profiling of Caenorhabditis elegans

A high-throughput microplate toxicity screening platform based on Caenorhabditis elegans

A Screenable In Vivo Assay for Mitochondrial Modulators Using Transgenic Bioluminescent Caenorhabditis elegans

Worm Generator: A System for High-Throughput in Vivo Screening

A novel assay for drug screening that utilizes the heat shock response of Caenorhabditis elegans nematodes

Biophysical phenotyping of C. elegans in a microfluidic chip for high-throughput drug screening

A microfluidic device for whole-animal drug screening using electrophysiological measures in the nematode C. elegans

A Sandwiched Microarray Platform for Benchtop Cell-Based High Throughput Screening

Integrating in vitro metabolomics with a 96-well high-throughput screening platform

High-throughput screening normalized to biological response: application to antiviral drug discovery

An update on the use of C. elegans for preclinical drug discovery: screening and identifying anti-infective drugs

WormScan: a technique for high-throughput phenotypic analysis of Caenorhabditis elegans

An automated microfluidic platform for toxicity testing based on Caenorhabditis elegans

Analyzing high-throughput assay data to advance the rapid screening of environmental chemicals for human reproductive toxicity

Microfluidics in High-Throughput Drug Screening: Organ-on-a-Chip and C. elegans-Based Innovations

High-throughput screening paradigms in ecotoxicity testing: Emerging prospects and ongoing challenges

Quantitative high throughput screening using a primary human three-dimensional organotypic culture predicts in vivo efficacy

High-Throughput Screening Assay Profiling for Large Chemical Databases

Novel Multiplexed High Throughput Screening of Selective Inhibitors for Drug-Metabolizing Enzymes Using Human Hepatocytes